Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2Sign in
← Cases

Afatinib

08ce6e29-f26e-5374-bf4e-c20140b23c79 · FDA Approved · targets EGFR, ERBB2_HER2, ERBB4_HER4

Afatinib

MeasuredReference

Afatinib targets ERBB4_HER4, EGFR, ERBB2_HER2. Strongest hallmark effect: tumor promoting inflammation.

Top hallmarks

  • tumor promoting inflammation3.7k
  • evading apoptosis2.9k
  • proliferation2.8k

Top pathways disrupted

  • allograft rejection7.0k
  • apical junction6.9k
  • pi3k akt mtor signaling6.3k

Resistance landscape — Afatinib

MeasuredReference

10 known oncogenic variants exist on Afatinib's top targets — see detail for inhibition impact.

Open in new tab